Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $12.56

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.5556.

Several research analysts recently commented on the stock. Stephens raised their price target on shares of NeoGenomics from $6.50 to $11.00 and gave the company an “overweight” rating in a report on Tuesday, September 2nd. Needham & Company LLC raised their price target on shares of NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Friday, August 29th. Piper Sandler set a $11.00 price target on shares of NeoGenomics and gave the company an “overweight” rating in a report on Monday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a report on Wednesday, October 8th. Finally, BTIG Research restated a “neutral” rating on shares of NeoGenomics in a report on Wednesday, July 30th.

Institutional Trading of NeoGenomics

Several large investors have recently bought and sold shares of the company. Moody National Bank Trust Division grew its position in NeoGenomics by 1.4% in the third quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock valued at $698,000 after acquiring an additional 1,227 shares in the last quarter. CWM LLC grew its position in NeoGenomics by 42.6% in the first quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 1,883 shares in the last quarter. Moors & Cabot Inc. grew its position in NeoGenomics by 20.0% in the second quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock valued at $88,000 after acquiring an additional 2,000 shares in the last quarter. State of Tennessee Department of Treasury grew its position in NeoGenomics by 3.6% in the second quarter. State of Tennessee Department of Treasury now owns 58,082 shares of the medical research company’s stock valued at $425,000 after acquiring an additional 2,039 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in NeoGenomics by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 65,004 shares of the medical research company’s stock valued at $475,000 after acquiring an additional 2,238 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Trading Up 2.1%

Shares of NEO stock opened at $10.67 on Tuesday. The firm has a market cap of $1.38 billion, a P/E ratio of -13.17 and a beta of 1.61. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $19.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.92 and a quick ratio of 3.58. The firm’s 50-day simple moving average is $8.39 and its 200-day simple moving average is $7.77.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.